This page shows the latest Triple-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Women diagnosed with cases of early triple-negative breast cancer (TNBC) where the disease had not progressed beyond the breast and lymph nodes – markers in stage 2 and 3 – were treated ... pre-operative chemotherapy increases the treatment response
European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... The therapy is now indicated as monotherapy for the treatment of adults with unresectable (cannot be removed by
O’Day also focused on the company’s oncology drugs and said: “Our marketed portfolio continues to expand with four new country approvals for Trodelvy for metastatic triple-negative breast cancer, ... Sales of Tecartus (brexucabtagene autoleucel)
Merck’s anti-PD-1 therapy, Keytruda, is approved in the Europe Union for certain patients with triple-negative breast cancer plus chemotherapy. ... Triple-negative breast cancer (TNBC) is an aggressive form of the disease with a high recurrence rate
unresectable or metastatic triple-negative breast cancer (TNBC). ... Gilead’s development programme for Trodelvy includes potential use in other TNBC and metastatic urothelial cancer, for hormone receptor-positive/human epidermal growth factor receptor
In response to the announcement of the early access scheme, cancer charity Breast Cancer NOW has criticised Gilead for failing to follow suit with Trodelvy (sacituzumab govitecan) in triple negative incurable ... Morgan. “These women don’t have time
More from news
Approximately 10 fully matching, plus 79 partially matching documents found.
For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug conjugate
MK-3475 was awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. ... BATON studies in colorectal cancer and metastatic triple negative breast cancer.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...